-
Everest Medicines Announces NMPA Full Approval of NEFECON, Broadening Treatment Access for IgA Nephropathy Patients in China
ACN Newswire
May 07, 2025
Everest Medicines announced that the supplemental New Drug Application (sNDA) for NEFECON has received full approval from the China National Medical Products Administration (NMPA).
-
Novartis Announces Iptacopan Met Primary Endpoint in Rare Kidney Disease IgA Nephropathy
americanpharmaceuticalreview
June 09, 2021
Novartis announced Phase II primary endpoint data showing investigational iptacopan (LNP023) – a first-in-class, oral, targeted factor B inhibitor – reduced protein in the urine (proteinuria), an increasingly recognized surrogate marker correlating ...
-
EC Grants Orphan Designation to Sparsentan for IgA Nephropathy
americanpharmaceuticalreview
February 24, 2021
?Travere Therapeutics announced the European Commission (EC) has granted orphan designation to sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder and a leading cause of end-stage kidney disease (ESKD).
-
Travere Announces Orphan Drug Designation for IgA Nephropathy Treatment
americanpharmaceuticalreview
January 20, 2021
Travere Therapeutics announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder and a leading cause of end-stage kidney disease (ESKD).
-
Aravive Initiates Trial of AVB-500 in Patients with Kidney Fibrosis
americanpharmaceuticalreview
December 23, 2019
Aravive announced the company has begun enrolling patients in the Phase 2a clinical trial of AVB-500 in patients with kidney fibrosis, specifically IgA Nephropathy (IgAN).
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight January 2025
